AR059911A1 - Cristales de tetomilast, metodos para prepararlos y composiciones farmaceuticas que los contienen. - Google Patents

Cristales de tetomilast, metodos para prepararlos y composiciones farmaceuticas que los contienen.

Info

Publication number
AR059911A1
AR059911A1 ARP070101070A ARP070101070A AR059911A1 AR 059911 A1 AR059911 A1 AR 059911A1 AR P070101070 A ARP070101070 A AR P070101070A AR P070101070 A ARP070101070 A AR P070101070A AR 059911 A1 AR059911 A1 AR 059911A1
Authority
AR
Argentina
Prior art keywords
powder
ray diffraction
diffraction spectrum
tetomilast
crystal
Prior art date
Application number
ARP070101070A
Other languages
English (en)
Inventor
S Aoki
K Nakaya
M Sota
M Ishigami
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38069222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR059911A1 publication Critical patent/AR059911A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Provee cristal de tetomilast. (1) Un cristal de hidrato de tetomilast que tiene un espectro de difraccion de rayos X en polvo que es sustancialmente igual que el espectro de difraccion de rayos X en polvo ilustrado en la fig. 2; (2) un cristal tetomilast anhidro tipo A que posee de un espectro de difraccion de rayos X en polvo que es sustancialmente igual que el espectro de difraccion de rayos X en polvo ilustrado en la fig. 4; (3) un cristal tetomilast anhidro tipo C que posee un espectro de difraccion de rayos X en polvo que es sustancialmente igual que el espectro de difraccion de rayos X en polvo ilustrado en la fig. 8; (4) un cristal solvato de tetomilast acetonitrilo que tiene un espectro de difraccion de rayos X en polvo que es sustancialmente igual que el espectro de difraccion de rayos X en polvo ilustrado en la fig. 10; y (5) una mezcla que consiste del cristal tetomilast anhidro tipo A anterior y un cristal tetomilast anhidro tipo B. Concordantemente, estos cristales son usados preferentemente en composiciones farmacéuticas para el tratamiento de enfermedades causadas por la generacion excesiva de las especies de oxígeno radiactivo tales como lípido peroxido.
ARP070101070A 2006-03-17 2007-03-16 Cristales de tetomilast, metodos para prepararlos y composiciones farmaceuticas que los contienen. AR059911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006075307 2006-03-17

Publications (1)

Publication Number Publication Date
AR059911A1 true AR059911A1 (es) 2008-05-07

Family

ID=38069222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101070A AR059911A1 (es) 2006-03-17 2007-03-16 Cristales de tetomilast, metodos para prepararlos y composiciones farmaceuticas que los contienen.

Country Status (27)

Country Link
US (4) US8501949B2 (es)
EP (4) EP1999128B1 (es)
JP (2) JP4182363B2 (es)
KR (6) KR101118943B1 (es)
CN (4) CN101365697B (es)
AR (1) AR059911A1 (es)
AT (1) ATE476433T1 (es)
AU (1) AU2007239906B2 (es)
BR (1) BRPI0706224A2 (es)
CA (4) CA2725810C (es)
CY (3) CY1111046T1 (es)
DE (1) DE602007008212D1 (es)
DK (3) DK2311832T3 (es)
ES (3) ES2390926T3 (es)
HK (3) HK1124062A1 (es)
IL (4) IL192237A (es)
MY (2) MY143808A (es)
NO (1) NO20083000L (es)
PH (1) PH12015502374A1 (es)
PL (3) PL1999128T3 (es)
PT (3) PT2311832E (es)
RU (2) RU2408597C2 (es)
SG (4) SG172707A1 (es)
SI (3) SI2311832T1 (es)
TW (1) TWI394753B (es)
WO (1) WO2007119496A1 (es)
ZA (2) ZA200805235B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186605B2 (en) 2016-10-06 2021-11-30 Kyowa Hakko Bio Co., Ltd. Crystal of cytidine diphosphate choline and production method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
DE69132944T2 (de) 1990-11-30 2002-11-21 Otsuka Pharma Co Ltd Azolederivate als Inhibitor von Superoxide-Radikalen
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
JP4300373B2 (ja) 1996-09-30 2009-07-22 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP4336913B2 (ja) 1999-02-12 2009-09-30 大塚製薬株式会社 アミド誘導体の製造方法
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003009844A1 (en) * 2001-07-24 2003-02-06 Otsuka Pharmaceutical Co., Ltd. Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease
JP3713577B2 (ja) 2001-07-24 2005-11-09 大塚製薬株式会社 慢性閉塞性肺疾患治療薬
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1613598B1 (en) * 2003-12-16 2011-10-19 Teva Pharmaceutical Industries, Ltd. Methods of preparing aripiprazole crystalline forms

Also Published As

Publication number Publication date
RU2009147223A (ru) 2011-06-27
ZA201001687B (en) 2010-11-24
MY143808A (en) 2011-07-15
SI1999128T1 (sl) 2010-12-31
PL1999128T3 (pl) 2010-12-31
WO2007119496A1 (en) 2007-10-25
KR20130003041A (ko) 2013-01-08
HK1159080A1 (en) 2012-07-27
KR101083611B1 (ko) 2011-11-16
KR101252994B1 (ko) 2013-04-15
KR101482374B1 (ko) 2015-01-14
EP2311832A1 (en) 2011-04-20
EP2311832B1 (en) 2012-08-22
KR101118943B1 (ko) 2012-02-27
US20150352095A1 (en) 2015-12-10
CA2725649C (en) 2013-05-14
CA2725698C (en) 2013-06-18
TW200813041A (en) 2008-03-16
IL214253A0 (en) 2011-08-31
PT1999128E (pt) 2011-01-20
JP5197196B2 (ja) 2013-05-15
ES2348630T3 (es) 2010-12-10
CY1111046T1 (el) 2015-06-11
NO20083000L (no) 2008-09-30
DK2206711T3 (da) 2012-10-08
ZA200805235B (en) 2010-07-28
EP1999128A1 (en) 2008-12-10
CN102174044A (zh) 2011-09-07
TWI394753B (zh) 2013-05-01
EP1999128B1 (en) 2010-08-04
SI2206711T1 (sl) 2012-12-31
CN102174044B (zh) 2014-02-26
ES2390957T3 (es) 2012-11-20
SG172706A1 (en) 2011-07-28
CY1113263T1 (el) 2016-04-13
JP2007277235A (ja) 2007-10-25
EP2206711B1 (en) 2012-08-22
CA2634100A1 (en) 2007-10-25
US20130184312A1 (en) 2013-07-18
CA2725810C (en) 2013-01-22
SG10201408225VA (en) 2015-01-29
US9145404B2 (en) 2015-09-29
SG172708A1 (en) 2011-07-28
CN102174046B (zh) 2013-12-25
RU2441002C2 (ru) 2012-01-27
HK1159079A1 (en) 2012-07-27
ES2390926T3 (es) 2012-11-19
IL192237A0 (en) 2009-02-11
CN102174045A (zh) 2011-09-07
DK1999128T3 (da) 2010-11-08
KR101168630B1 (ko) 2012-07-30
EP2206711A2 (en) 2010-07-14
PL2311832T3 (pl) 2013-01-31
CA2725649A1 (en) 2007-10-25
PL2206711T3 (pl) 2013-01-31
KR20110087350A (ko) 2011-08-02
RU2008127324A (ru) 2010-01-10
PT2206711E (pt) 2012-08-31
US20140113937A1 (en) 2014-04-24
US20100222590A1 (en) 2010-09-02
SG172707A1 (en) 2011-07-28
CY1113262T1 (el) 2016-04-13
PT2311832E (pt) 2012-08-30
KR20100127886A (ko) 2010-12-06
CA2725698A1 (en) 2007-10-25
EP2206711A3 (en) 2010-10-13
RU2408597C2 (ru) 2011-01-10
IL214252A0 (en) 2011-08-31
EP2311833A1 (en) 2011-04-20
KR20110135427A (ko) 2011-12-16
KR20080077260A (ko) 2008-08-21
IL214254A0 (en) 2011-08-31
AU2007239906B2 (en) 2010-07-29
US8501949B2 (en) 2013-08-06
ATE476433T1 (de) 2010-08-15
BRPI0706224A2 (pt) 2011-03-22
CA2725810A1 (en) 2007-10-25
US8993601B2 (en) 2015-03-31
CN102174046A (zh) 2011-09-07
DK2311832T3 (da) 2012-10-08
DE602007008212D1 (de) 2010-09-16
HK1124062A1 (en) 2009-07-03
KR20110136902A (ko) 2011-12-21
CN101365697B (zh) 2011-11-23
PH12015502374A1 (en) 2017-03-22
JP2008285498A (ja) 2008-11-27
IL214253A (en) 2014-01-30
JP4182363B2 (ja) 2008-11-19
CA2634100C (en) 2011-08-23
MY151343A (en) 2014-05-15
CN101365697A (zh) 2009-02-11
SI2311832T1 (sl) 2012-12-31
AU2007239906A1 (en) 2007-10-25
IL192237A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
SV2016005229A (es) Inhibidores de syk
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
ECSP14013324A (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
EA201490357A1 (ru) Индазолы
AR078850A1 (es) Composiciones terapeuticas concentradas de fosfolipidos
DOP2014000051A (es) Imidazopiridazinas sustituidas con amino
AR097325A1 (es) Pirroles anillados
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
EA201390010A1 (ru) Замещенные триазолопиридины
AR050914A1 (es) Agonista receptor de vasopresina peptidico
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
UY35293A (es) Isotiazoles sustituidos con amino
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
MY184433A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
CL2020002604A1 (es) Ciertos compuestos de pladienolida y métodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure